Eli Lilly’s marketed GLP-1 prescribing pathway could get more complicated after Counsel Health’s announced acquisition by smart-ring maker Oura, according to experts commenting on the deal’s potential conflict-of-interest implications. Counsel Health, already featured by Lilly as a GLP-1 provider, said the Oura acquisition would give clinicians access to smart-ring data to support interpretation and downstream diagnosis or treatment decisions. The concern raised by experts is how integrated consumer health data streams could affect prescribing workflows when a major drugmaker is simultaneously promoting the telehealth channel.